K
KALA BIO, Inc. (KALA)
NCM – Real Time Price. Currency in USD
3.12
-0.79 (-20.20%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.12
-0.79 (-20.20%)
At close: May 12, 2026, 4:00 PM EDT
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
| Name | Position |
|---|---|
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
| Dr. Justin Hanes Ph.D. | Founder & Chair of the Scientific Advisory Board |
| Mr. Avi Minkowitz | CEO, CFO & Director |
| Mr. Carl Rennie | Executive Director of Account Management |
| Mr. Josiah Craver CPA | Senior VP & Corporate Controller |
| Mr. Patrick Bedell | Executive Director of Trade & Alternate Channels |
| Mr. Vincent Kosewski | Senior VP of Manufacturing & Supply Chain Management |
| Ms. Jill S. Steier | Executive Director of Investor Relations & Corporate Communications |
| Ms. Mary Reumuth CPA | Treasurer & Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | S-3 | kalabio_s3.htm |
| 2026-04-15 | 10-K | kala-20251231x10k.htm |
| 2026-03-31 | NT 10-K | kalabio_nt10k.htm |
| 2026-03-17 | D | |
| 2026-03-04 | 8-K | kalabio_8k.htm |
| 2026-02-20 | 8-K | kalabio_8k.htm |
| 2026-02-13 | D | |
| 2026-02-13 | CORRESP | filename1.htm |
| 2026-02-10 | S-3 | kalabio_s3.htm |
| 2026-02-05 | 8-K | kalabio_8k.htm |